Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENMAB A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENMAB A/S's regulatory disclosures and financial reporting.
Genmab A/S is convening its Annual General Meeting on March 19, 2026 in Copenhagen and outlining key proposals for shareholder approval. Shareholders will be asked to adopt the audited 2025 Annual Report, grant discharge to the Board and Executive Management, and carry forward the profit of USD 963 million to retained earnings rather than paying a dividend.
The agenda includes an advisory vote on the 2025 Compensation Report, re-election of six directors, and re-appointment of Deloitte as auditor, including a limited assurance engagement on sustainability statements. Board and committee fees for 2026 are proposed to remain at 2025 levels, with a base fee of DKK 600,000 and specified supplements for chair, deputy chair and committee roles, plus restricted stock units under the remuneration policy.
Genmab’s Board also proposes a share capital reduction by nominally DKK 1,900,000 through cancellation of 1,900,000 treasury shares that were repurchased for a total of DKK 2,473,734,807.58, at an average price of DKK 1,301.97 per share. Following this, the Articles of Association would be amended to reflect the reduced share capital, which is currently DKK 64,238,408 divided into shares of DKK 1 each, with one vote per share.
Genmab A/S is launching a share buy-back program of up to 342,130 shares with a maximum total value of 725 million DKK. The program is designed to meet obligations under the company’s Restricted Stock Unit program and will run from February 18, 2026, and is expected to end no later than March 31, 2026, unless suspended or terminated.
Genmab has given a non-discretionary mandate to Danske Bank, which will independently execute purchases on Nasdaq Copenhagen and multilateral trading facilities under EU market abuse and Safe Harbour rules. As of February 17, 2026, Genmab holds 2,615,851 treasury shares, equal to 4.07% of its share capital.
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 6.6% beneficial stake in Genmab A/S common stock on a Schedule 13G/A. They disclose beneficial ownership of 4,237,472 shares, with Orbis holding 4,229,662 shares and Allan Gray holding 7,810 shares.
Each firm has sole voting and dispositive power over its respective holdings and reports no shared power. They classify themselves as non-U.S. institutions equivalent to investment advisers and state the securities are held in the ordinary course of business, not to change or influence control of Genmab A/S.
Genmab A/S has filed its 2025 annual report on Form 20-F, outlining a biotech business heavily driven by antibody medicines and partnership revenues. In 2025, royalties from Johnson & Johnson on multiple myeloma drug DARZALEX accounted for 66% of revenue, with key patents beginning to expire from 2029 in major markets.
The report highlights rapid growth from 548 employees in 2019 to 3,029 by the end of 2025 and an expanded late-stage pipeline, including assets added through the Merus acquisition such as Rina-S and petosemtamab. Genmab discloses extensive risks around clinical trial failure, dependence on collaborators, manufacturing via a limited number of third-party CMOs (including Chinese suppliers), cybersecurity, ESG expectations and climate-related disruption. The company reports 64,238,408 ordinary shares outstanding (including those underlying ADSs) and prepares its financials in US dollars under IFRS Accounting Standards.
Genmab A/S files an updated set of Articles of Association, outlining its capital structure, governance framework, and equity incentive authorizations. The company’s share capital is set at DKK 64,238,408, divided into shares of DKK 1.
The Board of Directors is authorized until March 12, 2029 to increase share capital by up to a nominal DKK 6,600,000, both with and without pre-emption rights. Separate authorizations allow issuance of employee warrants under several 750,000-warrant programs and convertible debt instruments convertible into up to nominal DKK 3,000,000 of new shares.
The Articles also formalize rules for general meetings, electronic communication with shareholders, employee representation on the Board, and an indemnification scheme for directors running until March 12, 2029, subject to exclusions for fraud, criminal offences, wilful misconduct, or gross negligence.
Genmab A/S has granted 32,806 restricted stock units (RSUs) and 34,307 warrants to employees of the company and its subsidiaries. Each RSU is awarded cost-free and gives a conditional right to one Genmab share of nominally DKK 1.
The fair value of each RSU equals the DKK 2,067 closing market price per Genmab share on the grant date. RSUs vest on the first banking day of the month following three years from grant, subject to conditions in the Board-approved RSU program.
Each warrant is also awarded cost-free, carries an exercise price of DKK 2,067 and entitles the holder to subscribe one share of nominally DKK 1. Using the Black-Scholes formula, the fair value of each warrant is DKK 658.81. Warrants vest after three years and expire seven years from grant under the company’s February 23, 2021 warrant program.
Genmab A/S reported that worldwide 2025 net trade sales of the cancer medicine DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on all worldwide net sales of both the intravenous and subcutaneous products under its exclusive license agreement with Johnson & Johnson. The filing also reiterates that Genmab is a biotechnology company focused on antibody-based medicines, with multiple approved therapies and a late-stage clinical pipeline.
Genmab A/S reported topline Phase 3 results from the EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In 483 patients ineligible for high-dose chemotherapy and transplant, subcutaneous epcoritamab monotherapy improved progression-free survival with a hazard ratio of 0.74 (95% CI 0.60–0.92) versus chemotherapy. Complete response rate, duration of response and time to next treatment also improved with epcoritamab.
Overall survival showed a hazard ratio of 0.96 (95% CI 0.77–1.20) and did not reach statistical significance. The safety profile appeared consistent with known risks, including cytokine release syndrome, neurologic events, infections and low blood counts as highlighted in the EPKINLY prescribing information. Genmab and AbbVie plan to discuss these results with global regulators and expect additional Phase 3 data for fixed-duration epcoritamab regimens in DLBCL during 2026.
Genmab A/S reported changes in its beneficial ownership of Merus N.V. following a cash tender offer. Through its wholly owned subsidiary, Genmab Holding II B.V., it accepted 71,463,077 Merus common shares at $97.00 per share on December 12, 2025, representing about 94.2% of Merus’s outstanding common shares at that time. During a subsequent offering period, the purchaser acquired an additional 120,752 shares on December 16, 2025 and 150,795 shares on December 17, 2025. After these transactions, Genmab, as parent of the purchasing subsidiary, is reported as indirectly beneficially owning over 71.7 million Merus shares.
Genmab A/S has filed an initial ownership report showing it now beneficially owns 71,463,077 common shares of Merus N.V., indirectly through its wholly owned subsidiary Genmab Holding II B.V. These shares were acquired in a tender offer that expired on December 12, 2025.
The accepted shares represent approximately 94.2% of Merus’s outstanding common shares. Tendering shareholders received a cash payment of $97.00 per share, without interest and less applicable withholding taxes, giving Genmab effective control of nearly all of Merus’s equity.